// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

Mim8 is associated with improved thrombin generation vs. emicizumab in patients with haemophilia A, with and without inhibitors

J. Windyga - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Hemophilia

Evithrom

Modeling gray platelet syndrome: longitudinal mouse studies and in vitro human iPSC-derived megakaryocytes to investigate clinical and cellular features

J. Collins - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Gray platelet syndrome

N/A

Modulation of plasmin inhibitor activities, using Affimer technology, improves the hypofibrinolytic environment in high vascular risk individuals

B. Alsayejh - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Molecular insights into the cause and treatment of congenital thrombocytopenia in mice lacking the co-inhibitory receptor G6b-B

A. MAZHARIAN - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Macrothrombocytopenia

L-Tyrosine

Molecular, laboratory and clinical characteristics of inherited antithrombin deficiency: a large, single centre cohort study from the United Kingdom.

K. Mayger - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Multi-centre performance evaluation of ADAMTS13 activity quantification using three different measurement technologies

E. Foxton - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Multicentre Performance Evaluation and Reference Range for an Immunoassay for the Quantitative Determination of Factor XIII Antigen on the cobas t 711 Analyser

M. B�chsel - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Multicentre Performance Evaluation and Reference Range for the Quantitative Determination of Factor IX Activity on the cobas t 711 Analyser

M. B�chsel - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

National Incidence of Bleeding-Related Hospitalisations and Mortality by Anatomical and ISTH site classification in England 2014-2019

K. Creeper - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Nationwide analysis of Pre-Hospital Tranexamic Acid in trauma patients at risk of bleeding

A. Almuwallad - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Trauma

Tranexamic acid

Next-generation FVIII mimetic, Mim8, does not interfere with non-factor VIII haemostasis assays.

A. Bowyer - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

FVIII

Non-invasive In Vivo Thrombus Imaging in Patients with Ischaemic Stroke or Transient Ischaemic Attack.

B. Whittington - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Transient Ischemic Attack

Elarofiban

Novel accreditation of European haemophilia treatment and gene therapy centres

A. Boban - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Hemophilia

N/A

Novel Flow Cytometric Diagnostic Assay for Primary Immune Thrombocytopenia.

P. Woolley - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Immune thrombocytopenia

N/A

Occult cancer assessment in a nurse-led DVT clinic

M. Rees - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Open-Source robotic microfluidic blood analysis using Raspberry Pi

R. Sariyer - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Optimal anticoagulation intensity for patients with COVID-19 treated with Tocilizumab

S. Bristogiannis - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Coronavirus disease

Tocilizumab

Optimizing Variant Curation Guidelines to Improve Clinical Genetic Testing and Diagnosis of von Willebrand Disease

K. Lee - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Paradigm shift in ITP treatment patterns in the era of the COVID-19 pandemic – opportunity to study real world outcomes from an established platform: Update from UK Adult ITP registry.

H. Miah - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Coronavirus disease

N/A

Patient outcomes of catheter directed thrombolysis for upper extremity deep vein thrombosis

Y. Tan - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Deep vein thrombosis

N/A

Copyright © 2026. QuantiNova All rights reserved